{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:16:42Z","timestamp":1768321002903,"version":"3.49.0"},"reference-count":116,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2010,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Imatinib is an inhibitor of the<jats:italic>BCR\u2013ABL<\/jats:italic>fusion gene product that characterizes chronic myeloid leukemia (CML), and of the related tyrosine kinases c\u2010KIT and platelet\u2010derived growth factor (PDGF) receptor. The drug is now included as front\u2010line therapy for CML and Philadelphia chromosome\u2010positive acute lymphoblastic leukemia in children and adolescents, though valid concerns about serious late sequelae remain unresolved and are important issues for further study. European and North American consortia have conducted phase I and II clinical trials of imatinib in children and adolescents with brain and other solid tumors that have provided little evidence of efficacy. Pediatr Blood Cancer 2010;55:18\u201325. \u00a9 2010 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/pbc.22484","type":"journal-article","created":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T14:37:22Z","timestamp":1270132642000},"page":"18-25","source":"Crossref","is-referenced-by-count":28,"title":["Imatinib mesylate in children and adolescents with cancer"],"prefix":"10.1002","volume":"55","author":[{"given":"Ronald D.","family":"Barr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,4]]},"reference":[{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.047"},{"key":"e_1_2_12_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.06.005"},{"key":"e_1_2_12_4_2","first-page":"538","volume-title":"Principles and practice of pediatric oncology","author":"Margolin JF","year":"2006"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-10-200305200-00010"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"e_1_2_12_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3032"},{"key":"e_1_2_12_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003262101"},{"key":"e_1_2_12_9_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.004283"},{"key":"e_1_2_12_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0950"},{"key":"e_1_2_12_11_2","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2006-031"},{"key":"e_1_2_12_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21132"},{"key":"e_1_2_12_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02353475"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-008-0730-x"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/320415a0"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1988.tb02907.x"},{"key":"e_1_2_12_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.3.925"},{"key":"e_1_2_12_18_2","first-page":"5778","article-title":"Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet\u2010derived growth factor receptor antagonist STI 571 through induction of apoptosis","volume":"61","author":"Sjoblom T","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_12_19_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.7.2558"},{"key":"e_1_2_12_20_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein\u2010tyrosine kinase inhibitor STI 571 inhibits in vitro signal transduction mediated by c\u2010kit and platelet\u2010derived growth factor receptors","volume":"295","author":"Buchdunger E","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_12_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200204000-00011"},{"key":"e_1_2_12_22_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0778-03"},{"key":"e_1_2_12_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0059"},{"key":"e_1_2_12_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.10.3465.3465"},{"key":"e_1_2_12_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2004.tb03251.x"},{"key":"e_1_2_12_26_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1984"},{"key":"e_1_2_12_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.MP.0000089778.48167.91"},{"key":"e_1_2_12_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403870"},{"key":"e_1_2_12_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880109"},{"key":"e_1_2_12_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.MP.0000043522.76788.0A"},{"key":"e_1_2_12_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23437"},{"key":"e_1_2_12_32_2","first-page":"108","article-title":"Platelet derived growth factor receptor (beta subunit) immunoreactivity in soft tissue tumors","volume":"66","author":"Palman C","year":"1992","journal-title":"Lab Invest"},{"key":"e_1_2_12_33_2","first-page":"78","article-title":"Intra\u2010abdominal small round cell tumor: Immunohistochemical evidence for up\u2010regulation of autocrine and paracrine growth factors","volume":"29","author":"Froberg K","year":"1999","journal-title":"Ann Clin Lab Sci"},{"key":"e_1_2_12_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1197-309"},{"key":"e_1_2_12_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800264"},{"key":"e_1_2_12_36_2","first-page":"3729","article-title":"Platelet\u2010derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: Evidence that the novel PDGF\u2010C and PDGF\u2010D ligands may play a role in the development of brain tumors","volume":"62","author":"Lokker NA","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_12_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-009-0550-3"},{"key":"e_1_2_12_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.22.1673"},{"key":"e_1_2_12_39_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1778"},{"key":"e_1_2_12_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh004"},{"key":"e_1_2_12_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_12_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_2_12_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441402"},{"key":"e_1_2_12_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573"},{"key":"e_1_2_12_45_2","first-page":"2167","article-title":"Treatment of Philadelphia chromosome\u2010positive, accelerated phase chronic myelogenous leukemia with imatinib mesylate","volume":"8","author":"Kantarjian H","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_12_46_2","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.V114.22.3894.3894","article-title":"Chronic eosinophilic leukemia (CEL) with FIPILI \u2013 PDGFR alpha re\u2010arrangement (F\/P): The response to imatinib (IM) is durable. A report of 33 patients with a follow\u2010up of 30\u201092 months","volume":"114","author":"Rondoni M","year":"2009","journal-title":"Blood"},{"key":"e_1_2_12_47_2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood.V114.22.340.340","article-title":"Significant higher rates of undetectable molecular residual disease and molecular responses with pegylated form of interferon a2a in combination with imatinib (IM) for the treatment of newly diagnosed chronic phase chronic myeloid leukemia (CML) patients (pts): Confirmatory results at 18 months of part 1 of the Spirit phase III randomized trial of the French CML Group (F1\u2010LMC)","volume":"114","author":"Guilhot F","year":"2009","journal-title":"Blood"},{"key":"e_1_2_12_48_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood.V114.22.339.339","article-title":"Randomised comparison of imatinib 800\u2009mg versus imatinib 400\u2009mg +\/\u2212 IFN in newly diagnosed BCR\/ABL positive chronic phase CML: Analysis of molecular remissions at 12 months; the German CML Study IV","volume":"114","author":"Hehlmann R","year":"2009","journal-title":"Blood"},{"key":"e_1_2_12_49_2","first-page":"353","article-title":"Discontinuation of imatinib therapy after achieving a molecular remission in chronic myeloid leukemia patients","volume":"114","author":"Mahon F\u2010X","year":"2009","journal-title":"Blood"},{"key":"e_1_2_12_50_2","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1182\/blood.V114.22.3290.3290","article-title":"Long term adherence to imatinib therapy is the critical factor for achieving molecular responses in chronic myeloid leukemia patients","volume":"114","author":"Bazeos A","year":"2009","journal-title":"Blood"},{"key":"e_1_2_12_51_2","first-page":"464","article-title":"Update on imatinib\u2010resistant chronic myeloid leukemia patients in chronic phase (CML\u2010CP) on nilotinib therapy at 24 months: Clinical response, safety and long\u2010term outcomes","volume":"114","author":"Kantarjian HM","year":"2009","journal-title":"Blood"},{"key":"e_1_2_12_52_2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.V114.22.1128.1128","article-title":"Dasatinib is well\u2010tolerated and efficacious in imatinib\u2010intolerant patients with chronic phase myeloid leukemia (CP\u2010CML)","volume":"114","author":"Khoury HJ","year":"2009","journal-title":"Blood"},{"key":"e_1_2_12_53_2","first-page":"352","article-title":"Safety and efficacy of subcutaneous\u2010administered omacetaxine mepesuccinate in chronic myeloid leukemia patients who are resistant or intolerant to two or more tyrosine kinase inhibitors \u2013 results of a multi\u2010centre phase 2\/3 study","volume":"114","author":"Cortes\u2010Franco J","year":"2009","journal-title":"Blood"},{"key":"e_1_2_12_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.04.036"},{"key":"e_1_2_12_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.08.019"},{"key":"e_1_2_12_56_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1239529"},{"key":"e_1_2_12_57_2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood.V114.22.342.342","article-title":"Chronic myeloid leukemia in pediatrics\u2014First results from study CML\u2010PAED II","volume":"114","author":"Suttorp M","year":"2009","journal-title":"Blood"},{"key":"e_1_2_12_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.10306"},{"key":"e_1_2_12_59_2","unstructured":"http:\/\/ctep.info.nih.gov\/reporting\/index.html(accessed August 11 2009)."},{"key":"e_1_2_12_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200211000-00020"},{"key":"e_1_2_12_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404051"},{"key":"e_1_2_12_62_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.2514"},{"key":"e_1_2_12_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403401"},{"key":"e_1_2_12_64_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-204156"},{"key":"e_1_2_12_65_2","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood.V114.22.3558.3558","article-title":"Imatinib as salvage therapy for refractory cGVHD: The interim analysis of the prospective GITMO multicenter study Gruppo Italiano Trapianto di Midollo Osseo","volume":"114","author":"Olivieri A","year":"2009","journal-title":"Blood"},{"key":"e_1_2_12_66_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_2_12_67_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-073528"},{"key":"e_1_2_12_68_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm049486a"},{"key":"e_1_2_12_69_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"e_1_2_12_70_2","first-page":"1259","article-title":"Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal","volume":"152","author":"Kindblom LG","year":"1998","journal-title":"Am J Pathol"},{"key":"e_1_2_12_71_2","doi-asserted-by":"publisher","DOI":"10.1097\/00125480-199901000-00003"},{"key":"e_1_2_12_72_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5350.577"},{"key":"e_1_2_12_73_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1079666"},{"key":"e_1_2_12_74_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.190"},{"key":"e_1_2_12_75_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20352"},{"key":"e_1_2_12_76_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mph.0000157790.81329.47"},{"key":"e_1_2_12_77_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000172190.79552.8b"},{"key":"e_1_2_12_78_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197706302962609"},{"key":"e_1_2_12_79_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1938"},{"key":"e_1_2_12_80_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.4284"},{"key":"e_1_2_12_81_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.4452"},{"key":"e_1_2_12_82_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.601"},{"key":"e_1_2_12_83_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21909"},{"key":"e_1_2_12_84_2","first-page":"7377","article-title":"Gleevec\u2010mediated inhibition of Rad 51 expression and enhancement of tumor cell radiosensitivity","volume":"63","author":"Russell J","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_12_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.05.008"},{"key":"e_1_2_12_86_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03881.x"},{"key":"e_1_2_12_87_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0829-4"},{"key":"e_1_2_12_88_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140665"},{"key":"e_1_2_12_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.03.007"},{"key":"e_1_2_12_90_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cco.0000228739.62756.df"},{"key":"e_1_2_12_91_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20249"},{"key":"e_1_2_12_92_2","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.140"},{"key":"e_1_2_12_93_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.98"},{"key":"e_1_2_12_94_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015545"},{"key":"e_1_2_12_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.12.020"},{"key":"e_1_2_12_96_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21996"},{"key":"e_1_2_12_97_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147785"},{"key":"e_1_2_12_98_2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood.V114.22.863.863","article-title":"Imatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CP): Results of the French national phase IV trial","volume":"114","author":"Millot F","year":"2009","journal-title":"Blood"},{"key":"e_1_2_12_99_2","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3324\/haematol.2009.008359","article-title":"Longitudinal growth retardation in a prepubertal girl with chronic myeloid leukemia on long\u2010term treatment with imatinib","volume":"94","author":"Schmid H","year":"2009","journal-title":"Haematologica"},{"key":"e_1_2_12_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61023-5"},{"key":"e_1_2_12_101_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-008-0251-8"},{"key":"e_1_2_12_102_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.150"},{"key":"e_1_2_12_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13554-4"},{"key":"e_1_2_12_104_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051140"},{"key":"e_1_2_12_105_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12373"},{"key":"e_1_2_12_106_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-104281"},{"key":"e_1_2_12_107_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22546"},{"key":"e_1_2_12_108_2","first-page":"459","article-title":"Hypophosphatemia during imatinib treatment of newly diagnosed chronic myeloid leukemia patients is associated with better response","volume":"114","author":"Casado LF","journal-title":"Blood;"},{"key":"e_1_2_12_109_2","first-page":"865","article-title":"Imatinib long term effects (ILTE) study: An international study to evaluate long\u2010term effects in CML patients","volume":"114","author":"Kim D\u2010W","year":"2009","journal-title":"Blood"},{"key":"e_1_2_12_110_2","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1182\/blood.V114.22.2200.2200","article-title":"Imatinib mesylate induced cardiotoxicity: A cardiac progenitor cell disease?","volume":"114","author":"Prezioso L","year":"2009","journal-title":"Blood"},{"key":"e_1_2_12_111_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1516-84842005000300005"},{"key":"e_1_2_12_112_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22498"},{"key":"e_1_2_12_113_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701824585"},{"key":"e_1_2_12_114_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.90"},{"key":"e_1_2_12_115_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-009-0292-7"},{"key":"e_1_2_12_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61165-9"},{"key":"e_1_2_12_117_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21937"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22484","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.22484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:31:35Z","timestamp":1739997095000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.22484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,7,15]]}},"alternative-id":["10.1002\/pbc.22484"],"URL":"https:\/\/doi.org\/10.1002\/pbc.22484","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}